electroCore, Inc.
NASDAQ:ECOR
electroCore, Inc.
electroCore, Inc. engages in the provision of non-invasive vagus nerve stimulation (nVNS) therapy. The company is headquartered in Rockaway, New Jersey and currently employs 52 full-time employees. The company went IPO on 2018-06-22. nVNS is a platform for bioelectronic medical therapy that modulates neurotransmitters and immune function through its effects on both the peripheral and central nervous systems. The firm is providing gammaCore device for the treatment of cluster headache and migraine, the acute treatment of migraine and episodic cluster headache, the acute and preventive treatment of migraines in adolescents, and paroxysmal hemicrania and hemicrania continua in adults. gammaCore permits patients to self-administer doses of nVNS on an as-needed basis for treatment of prevent multiple types of headache pain via the vagus nerve. The gammaCore therapy is also used to treat primary headache, including migraine, cluster headache (CH), hemicrania continua and paroxysmal hemicrania (PH) and coronavirus (COVID-19).
electroCore, Inc. engages in the provision of non-invasive vagus nerve stimulation (nVNS) therapy. The company is headquartered in Rockaway, New Jersey and currently employs 52 full-time employees. The company went IPO on 2018-06-22. nVNS is a platform for bioelectronic medical therapy that modulates neurotransmitters and immune function through its effects on both the peripheral and central nervous systems. The firm is providing gammaCore device for the treatment of cluster headache and migraine, the acute treatment of migraine and episodic cluster headache, the acute and preventive treatment of migraines in adolescents, and paroxysmal hemicrania and hemicrania continua in adults. gammaCore permits patients to self-administer doses of nVNS on an as-needed basis for treatment of prevent multiple types of headache pain via the vagus nerve. The gammaCore therapy is also used to treat primary headache, including migraine, cluster headache (CH), hemicrania continua and paroxysmal hemicrania (PH) and coronavirus (COVID-19).
Record Revenue: Revenue for Q3 2025 reached a record $8.7 million, up 33% from last year and 18% sequentially.
Guidance Raised: Full-year 2025 revenue guidance was increased to $31.5–$32.5 million.
Growth Drivers: Strong VA channel performance, launch of Quell Fibromyalgia, and renewed growth in Truvaga sales drove results.
Profitability Delayed: Management is investing in growth and expects positive adjusted EBITDA in the second half of 2026, pushing back earlier profitability targets.
Gross Margins: Gross margin remained robust at 86%, up from 84% last year.
Strategic Investments: Recent acquisition of NeuroMetrix’s Quell portfolio, expansion in managed care, wellness, and international channels highlighted.
Cash Position: Cash at September 30, 2025, was $13.2 million, with projected year-end cash of $10.5 million.
Litigation Update: Ongoing legal action against a European copycat device company was noted, with management focused on winning the case.
